Bert L. Lum

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock et al. · Journal of Clinical Oncology · 2010 · 440 citations

Life Sciences, Oncology, Pharmacology +17

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

Jianfeng Lü, René Bruno, Steve Eppler et al. · Cancer Chemotherapy and Pharmacology · 2008 · 346 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +14

Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

Peter L. Greenberg, Sandra J. Lee, Ranjana H. Advani et al. · Journal of Clinical Oncology · 2004 · 232 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

Jie Ling, Kim A. Johnson, Zhuang Miao et al. · Drug Metabolism and Disposition · 2005 · 222 citations

Medicine, Pharmacokinetics, Pharmacology +14

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development

Gillian S. Smelick, Timothy P. Heffron, Laura Chu et al. · Molecular Pharmaceutics · 2013 · 188 citations

Medicine, Oncology, Pharmacology +14